Pharma, Biotech Clinical Trial Leaders to Convene for 3rd Annual DrugDev Summit to Promote Collaboration, Technology Innovation, Engaged Sites, and More Informed Patients

The 2017 DrugDev Summit

Imagine the best minds in pharma and biotech gathering together, all fearless in their dedication to changing everything to speed the delivery of many more new treatments to millions of patients, and there you have the DrugDev Summit.

DrugDev, a QuintilesIMS company, will gather the most innovative minds in pharma and biotech at the third annual DrugDev Summit, November 7-8, 2017 in Philadelphia, PA. The DrugDev Summit is a two-day collaborative conference that brings together the world’s most progressive clinical research leaders for best practice case studies, keynote presentations, lively breakout sessions, hands-on training, and previews of new DrugDev technology-based solutions.

Featuring a client-driven agenda and highlighted by inspiring industry keynotes (announcements to come soon), last year’s Summit welcomed expert speakers from host company Merck, Janssen, Pfizer, Novartis, Eli Lilly, ICON, Boehringer-Ingelheim, Incyte, Alkermes, BioMarin, Chesapeake IRB, Radiant Research, and Emerson Clinical Research Institute. Register for the 2017 DrugDev Summit here.

“The 2016 DrugDev Summit was a very engaging event,” said Dawn Furey, Executive Director/Head, Global Operations, at Merck. “I didn’t think I would stay for the entire two days given my competing priorities, but I couldn’t step away. It was great.”

DrugDev expects more than 125 clinical leaders to attend this year’s Summit, which promotes three pillars of clinical research optimization – collaboration, standardization, and a beautiful technology experience – to transform the quality, transparency and efficiency of clinical trials. Summit participants gain actionable advice and inspiration from sponsors, sites and patients as they network in an organized yet congenial setting. The invitation-only event is complimentary for all sponsors, CROs and sites using DrugDev technology on nearly 2,000 clinical programs.

DrugDev President and CEO Ibs Mahmood said, “Imagine the best minds in pharma and biotech gathering together, all fearless in their dedication to changing everything to speed the delivery of many more new treatments to millions of patients, and there you have the DrugDev…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *